ASPIC

A team of IPATIMUP researchers had previously demonstrated that alterations in the telomerase gene are common to different types of cancer, including tumors of the skin, brain, bladder, and thyroid and are associated with increased levels of this enzyme in tumors. The same team now published a study in Journal of Investigative Dermatology, where they analyzed two types of skin cancer, melanoma and basal cell carcinoma, and demonstrates that telomerase gene mutations are associated with sun exposure and are also associated with a poorer prognosis in melanoma.

Uma equipa de investigadores do IPATIMUP tinha anteriormente demonstrado que alterações no gene da Telomerase são comuns a diferentes tipos de cancro, incluindo tumores da pele, do cérebro, da bexiga e da tiróide e estão associadas ao aumento dos níveis desta enzima nos tumores. A mesma equipa publicou agora um estudo na revista Journal of Investigative Dermatology, onde analisou dois tipos de cancro de pele, melanomas e carcinomas basocelulares, e demonstra que as mutações no gene da Telomerase se associam a exposição solar.

Authors and Affiliattions:

Leonor Miller-Fleming,^a,^b, Pedro Antas,^a, Teresa Faria Pais,^a, Joshua L. Smalley,^b,c, Flaviano Giorgini,^b,1,

and Tiago Fleming Outeiro,^a,d,e,1

a. Instituto de Medicina Molecular, 1649-028 Lisbon, Portugal;

b. Department of Genetics, University of Leicester, Leicester LE1 7RH, United Kingdom;

Um grupo de cientistas do Instituto de Medicina Molecular (IMM), liderado por Tiago Outeiro, e investigadores na Alemanha e no Reino Unido, estudaram um gene associado à doença de Parkinson e a forma como atua, abrindo portas ao desenvolvimento de novas estratégias terapêuticas contra esta doença, mas também contra o cancro. O trabalho de investigação vem mostrar que a doença de Parkinson pode ter uma causa genética - até recentemente os indícios apontavam para causas ambientais - trazendo nova esperança para o seu tratamento.

Professors Carlos Caldas and Yosef Yarden recently wrote a position paper on the behalf of the European Association for Cancer Research, which was published in the European Journal of Cancer (EJC). It describes the irreplaceable leading role of basic research in the future of cancer therapy, and how allocating resources to basic research could be the key to unlocking new achievements in personalized cancer treatment. 

Professors Carlos Caldas and Yosef Yarden recently wrote a position paper on the behalf of the European Association for Cancer Research, which was published in the European Journal of Cancer (EJC). It describes the irreplaceable leading role of basic research in the future of cancer therapy, and how allocating resources to basic research could be the key to unlocking new achievements in personalized cancer treatment. 

Pen Bron Hotel, La Turballe, France

1 - 4 October 2014

See more informations here: http://www.cgo-workshop-vecto.fr/

Pen Bron Hotel, La Turballe, France

1 - 4 October 2014

See more informations here: http://www.cgo-workshop-vecto.fr/

Università degli Studi di Ferrara, Ferrara, Italy

11-13 September 2014

See more informations here: http://www.cancerologia.it/index.php?lang=en

Tumor cells often have aberrant post-translational modifications of their proteins. In bladder cancer, one of these modifications is the sialyl-Tn (STn) glycan, which is not expressed by normal cells and is highly expressed in high-grade bladder cancer cells. It is known that the immune response is affected by tumor cells, promoting tumor progression. However, little is known about the role of STn in the immune response and its influence on immune cells. Dendritic cells (DCs) play a crucial role in the immune response against tumor cells.